Aardvark Therapeutics, Inc. (AARD)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Aardvark Therapeutics, Inc. reported revenue of $0. The company ran a net loss. It held $117.18M in total assets against $10.55M in total liabilities.
Key ratios (FY2025)
-54.0%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | — | — |
| Operating Income | -$62.73M | -$22.79M | — |
| Net Income | -$57.59M | -$20.59M | — |
| EPS (Diluted) | $-2.93 | $-5.15 | — |
| Total Assets | $117.18M | $77.51M | — |
| Total Liabilities | $10.55M | $5.39M | — |
| Shareholders' Equity | $106.63M | -$54.64M | -$34.80M |
| Cash & Equivalents | $47.05M | $61.64M | — |
| Operating Cash Flow | -$54.17M | -$18.09M | — |
| Capital Expenditures | $95.0K | $109.0K | — |
| Shares Outstanding | 21.82M | 4.07M | — |